ROCKVILLE, Md., May 7, 2015 /PRNewswire/ -- Synthetic Biologics,
Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company
developing therapeutics to protect the microbiome while targeting
pathogen-specific diseases, announced Maureen Early joined the team in the newly
created position of Vice President, Commercial. In her new role,
Ms. Early will lead all commercial and marketing efforts for the
Company's current and future product portfolio.
"Maureen has over 20 years of global and domestic strategic
marketing executive experience in the pharmaceutical industry
working on products from pre-launch through post-launch," said
Jeff Riley, President and CEO.
"During her career she has successfully launched several products,
created effective anti-infective marketing programs and developed
solutions to optimize brand lifecycles. Her strong track record
should be of enormous benefit to Synthetic Biologics as we enter
our next phase of development and growth. I look forward to working
with Maureen and her team as we move our microbiome-focused product
portfolio through the clinic and plan for commercial entry."
Ms. Early was President and Co-founder of Upside Endeavors, a
privately owned, independent medical strategic and communications
company, focused in the specialty therapeutic areas of oncology,
hematology, infectious diseases and inflammation. She was
responsible for business development, project execution, daily
operations and was heavily involved in the launch and lifecycle
planning of many products, including Prevnar 13® for adults and
pediatrics, Relistor®, Tygacil®, Zyvox®, Remicade®, Stelara®,
Zytiga® and Erbitux®. Prior to founding Upside Endeavors, Maureen
worked for Rhone Poulenc Rorer/Aventis in various medical and
marketing roles in both the areas of Infectious Disease and
Oncology.
Ms. Early holds an M.B.A. in International Business from St.
Joseph's University and a B.S. degree in Medical Technology with a
focus in Microbiology from Marywood
College, Scanton, PA.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a
microbiome-focused, clinical-stage company developing
therapeutics to protect the microbiome while targeting
pathogen-specific diseases. The Company is developing an oral
biologic to protect the gut microbiome from intravenous (IV)
antibiotics for the prevention of C. difficile infection and
an oral statin treatment to reduce the impact of methane producing
organisms on irritable bowel syndrome with constipation (IBS-C). In
addition, the Company is developing a monoclonal antibody
combination for the treatment of Pertussis in collaboration with
Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug
for the treatment of relapsing-remitting multiple sclerosis (MS)
and cognitive dysfunction in MS. For more information, please visit
Synthetic Biologics' website at www.syntheticbiologics.com.
Prevnar 13® is a registered trademark of Wyeth LLC.
Relistor® is a registered trademark of Valeant Pharmaceuticals
(formerly Salix Pharmaceuticals) under license from Progenics
Pharmaceuticals.
Tygacil® is a registered trademark of Wyeth LLC.
Zyvox® is a registered trademark of Pfizer.
Remicade® is a registered trademark of Janssen Biotech, Inc.
Stelara® is a registered trademark of Janssen Biotech, Inc.
Zytiga® is a registered trademark of Janssen Biotech, Inc.
Erbitux® is a registered trademark of ImClone LLC, a wholly-owned
subsidiary of Eli Lilly and Company.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding our continued
development pipeline, our intent to move our clinical programs
forward and plan for commercial entry and the expected
contributions of Ms. Early. The forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from those reflected in
Synthetic Biologics' forward-looking statements include, among
others, a failure to successfully integrate the new management and
other factors described in Synthetic Biologics' report on Form 10-K
for the year ended December 31, 2014
and any other filings with the SEC. The information in this release
is provided only as of the date of this release, and Synthetic
Biologics undertakes no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
Logo- http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/maureen-early-named-vice-president-commercial-of-synthetic-biologics-300079105.html
SOURCE Synthetic Biologics, Inc.